The employment of a "one size fits all" strategy, that is, a comparable line of therapy or the use of the same drug/medicine, that too in a conventional method, to cure a certain condition, has been witnessed for several decades. Rather than specific human characteristics, this strategy is linked to unique genetic constitutions and processes. Precision oncology has the potential to improve patient prediction, treatment, and follow-up care dramatically. As a result of recent biotechnological developments, identifying the various and diverse biological components involved to carcinogenesis has only lately become possible. The main goal of this chapter is to bridge the gap between Precision Oncology research and clinical practise by raising awareness among scientists, clinicians, and the general public, as well as providing a detailed representation of all advances made in the field, taking into account almost all aspects and possibilities. It also gives a thorough picture of the genes linked to many cancer types, including overlapping genes that are involved in numerous cancers. Knowing a patient's genetic information and the genes that are susceptible to mutations can aid in accurate diagnosis and the delivery of the best customised medicines, reducing the risk of treatment failure, which is common in cancer therapy. This chapter covers all aspects of Precision Oncology and gives an overview of overlapping genes as well as genes with cancer-causing mutations. This gathered data could aid future clinical investigations and academic research aimed at predicting and preventing cancer.
Author(S) Details
Sohini Kulavi
Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, India.
Sirshendu Chatterjee
Department of Biotechnology, Techno India University, West Bengal, India.
Chandreyi Ghosh
Department of Biotechnology, Techno India University, West Bengal, India.
Moumita Saha
Department of Biotechnology, Techno India University, West Bengal, India.
View Book:- https://stm.bookpi.org/CAPRD-V6/article/view/5156
No comments:
Post a Comment